Lazard Asset Management LLC Has $109.06 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Lazard Asset Management LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 3.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,267,873 shares of the company’s stock after selling 45,550 shares during the quarter. Lazard Asset Management LLC’s holdings in Novo Nordisk A/S were worth $109,062,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Diversified Trust Co lifted its holdings in shares of Novo Nordisk A/S by 13.9% in the fourth quarter. Diversified Trust Co now owns 3,246 shares of the company’s stock worth $279,000 after acquiring an additional 395 shares during the last quarter. ORG Partners LLC increased its holdings in Novo Nordisk A/S by 181.7% in the 4th quarter. ORG Partners LLC now owns 1,003 shares of the company’s stock worth $86,000 after purchasing an additional 647 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Novo Nordisk A/S by 0.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 290,489 shares of the company’s stock valued at $24,988,000 after purchasing an additional 1,051 shares in the last quarter. Fiduciary Alliance LLC grew its holdings in shares of Novo Nordisk A/S by 11.4% during the fourth quarter. Fiduciary Alliance LLC now owns 8,107 shares of the company’s stock worth $697,000 after purchasing an additional 829 shares during the last quarter. Finally, Capital Investment Advisors LLC boosted its position in Novo Nordisk A/S by 12.1% during the 4th quarter. Capital Investment Advisors LLC now owns 4,435 shares of the company’s stock worth $382,000 after buying an additional 478 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO stock opened at $65.75 on Monday. The company has a fifty day simple moving average of $69.21 and a two-hundred day simple moving average of $85.83. The firm has a market capitalization of $295.06 billion, a P/E ratio of 19.98, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $79.17 billion. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NVO has been the topic of several analyst reports. Guggenheim cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. Finally, Hsbc Global Res upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.